China released its 2025 national adverse drug reaction monitoring report, highlighting key pharmacovigilance trends and post-market safety monitoring activities.
Key highlights:
- Provides insights into adverse event reporting trends
- Highlights post-marketing safety monitoring priorities
- Supports stronger pharmacovigilance compliance
- Helps manufacturers improve risk management strategies
This update is important for companies managing post-market drug safety requirements.
Source
Select Mandate HA
Select Mandate Function